Drug Profile
Trafermin - Kaken Pharmaceutical
Alternative Names: CAB 2001; Fiblast Spray; KCB-1; KCB-1B; KCB-1D; REGROTH Dental KitLatest Information Update: 14 Sep 2018
Price :
$50
*
At a glance
- Originator Scios
- Developer Kaken Pharmaceutical; Olympus Corporation; Scios
- Class Fibroblast growth factors; Peptide fragments; Vascular disorder therapies
- Mechanism of Action Fibroblast growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Skin ulcer
- Registered Periodontitis
- Discontinued Coronary disorders; Diabetic foot ulcer; Fracture; Peripheral vascular disorders; Postmenopausal osteoporosis; Stroke